Kala Bio (KALA) Common Equity (2016 - 2026)
Kala Bio's Common Equity came in at $9.04 million for Q2 2026, compared with -$3.21 million a year earlier and down 16.0% from the prior quarter.
Powered by 
Analysis
Kala Bio (KALA) Common Equity (2016 - 2026) Analysis & Trends
At the end of FY2025, Kala Bio's Common Equity was $7 million, down 43.3% from FY2024.
- Common Equity carries a five-year compound annual growth rate of -41.3% (FY2020 to FY2025).
- Going back by year, Common Equity was $12.33 million in FY2024 (+64.3%), $7.5 million in FY2023 (-60.5%), $18.97 million in FY2022 (+12.9%) and $16.8 million in FY2021 (-83.2%).
- The five-year range for quarterly Common Equity is -$31.55 million (Q2 2022) to $61.47 million (Q3 2021).
- Year-over-year, Common Equity increased in two of the last five quarters, with growth averaging 11.3%.
- The fastest year-over-year change in Common Equity over five years came in Q1 2026 (growth of 88.5%), and the weakest in Q4 2021 (a decline of 83.2%).
- Business Quant data shows KALA's Common Equity at $10.76 million (Q1 2026), $7 million (Q4 2025) and -$8.67 million (Q3 2025) in the three quarters before Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn | 84.97 Bn |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn | -5.94 Bn |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn | 41.98 Bn |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn | 41.95 Bn |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn | 50.37 Bn |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn | 11.69 Bn |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn | 11.83 Bn |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn | 85.49 Bn |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn | 20.25 Bn |
| 10 | Kala Bio | 6.57 Mn | 6.57 Mn | - | 9.04 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 9.04 Mn |
| Mar 31, 2026 | 10.76 Mn |
| Dec 31, 2025 | 7.00 Mn |
| Sep 30, 2025 | -8.67 Mn |
| Jun 30, 2025 | -3.21 Mn |
| Mar 31, 2025 | 5.71 Mn |
| Dec 31, 2024 | 12.33 Mn |
| Sep 30, 2024 | 6.86 Mn |
| Jun 30, 2024 | 13.72 Mn |
| Mar 31, 2024 | 6.66 Mn |
| Dec 31, 2023 | 7.50 Mn |
| Sep 30, 2023 | 11.22 Mn |
| Jun 30, 2023 | 17.49 Mn |
| Mar 31, 2023 | 23.46 Mn |
| Dec 31, 2022 | 18.97 Mn |
| Sep 30, 2022 | -968,000.00 |
| Jun 30, 2022 | -31.55 Mn |
| Mar 31, 2022 | -5.28 Mn |
| Dec 31, 2021 | 16.80 Mn |
| Sep 30, 2021 | 61.47 Mn |
API Access
Kala Bio Common Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=common-equity&ticker=KALA&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "common-equity", "ticker": "KALA", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=common-equity&ticker=KALA&period=max&api_key=YOUR_API_KEY");
const data = await res.json();